Moderna Total Current Liabilities

Moderna (MRNA) currently reports a total current liabilities of $2.5B as of June 2026. That compares with $1.6B in the prior-year period — up 61.2% year over year. Use the charts on this page to explore Moderna's total current liabilities history and peer comparisons.

Moderna's total current liabilities increased from $1.6B to $2.5B — a 61.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Moderna reported $2.5B in total current liabilities as of June 2026. That compares with $1.6B in the prior-year period — up 61.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $2.5B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Moderna, and consider following MRNA for alerts when major investors trade the stock.

Moderna is classified in the Healthcare sector. On total current liabilities, it currently shows $2.5B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRNA with unrelated industries.